A Phase IIb Study of Nabiximols for Spasticity Due to Neuromyelitis Optica Spectrum Disorders

Inclusion Criteria: * Confirmed diagnosis of NMOSD, meeting the International Panel for NMO Diagnosis (IPND) NMOSD criteria (Appendix 1), including NMOSD with AQP4-IgG, and NMOSD without AQP4-IgG * Aged between 18 years or older, at the time of signing the informed consent * Willing and able to give informed consent and to participate in all study procedures * Moderate to severe spasticity, as defined by a score of \> 3 on the 0-10 numerical rating scale for spasticity (NRS-S) at the time of screening * Reports NMOSD-related spasticity symptoms ongoing for at least 6 months * Spasticity is determined to be causally related to an NMOSD attack in the opinion of the investigator * No relapses, and otherwise stable disease (i.e. no significant recovery from relapse or other change in disability) for at least 6 months, in the opinion of the investigator * Anti-spasticity regimen, if on medications, maintained at a stable dose for the 30 days prior to enrollment without adequate relief of spasticity symptoms. * Willing to maintain a stable dose of non-study-related anti-spasticity medication for the duration of the study, barring significant changes to their medical condition. * Willing to allow his or her primary care doctor and primary neurologist, if appropriate, to be notified of participation in the study. * Documentation of negative MOG-IgG, if diagnosis is NMOSD without AQP4-IgG positive status. Participant with presumptive diagnosis of NMOSD without AQP4-IgG and no prior M…